4-[[(4-Fluorophenyl)imino]methyl]-phenol CAS 3382-63-6 Ezetimibe Intermedia Puritas ≥99.0% Factory
Manufacturer Supple;Qualitas et auctor pretium
Supple Commercial Ezetimibe (CAS: 163222-33-1) Intermedia:
(S)-(+)-4-Phenyl-2-oxazolidinone CAS: 99395-88-7
CAS: 112022-83-0
4-(4-Fluorobenzoyl) acidum butyricum CAS: 149437-76-3
4-[[(4-Fluorophenyl)imino]methyl]-phenol CAS: 3382-63-6
N-(4-(Benzyloxy) benzyliden) -4-fluoroaniline CAS: 70627-52-0
(3R,4S)-4-[4-(Benzyloxy)phenyl]-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-oxopropyl]azetidin-2-one CAS: 190595-65 -4
(4S)-3-[5-(4-Fluorophenyl)-1,5-dioxopenyl]-4-phenyl-2-oxazolidinone CAS: 189028-93-1
(4S) -3-[(5S)-5-(4-Fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one CAS: 189028-95-3
Ezetimibe CAS: 163222-33-1
Nomen chemicum | 4-[[(4-Fluorophenyl)imino]methyl]-phenol |
CAS Number | 3382-63-6 |
CATTUS Number | RF-PI145 |
Stock Status | In Stock, Productio Ascendite ad Tons |
Formulae hypotheticae | C13H10FNO |
M. Pondus | 215.22 |
Liquescens punctum | 179.0 ad 183.0℃ |
Brand | Ruifu Chemical |
Item | Specifications |
Aspectus | Off-White ad Alba pulveris |
Puritas / Analysis Methodus | ≥99.0% (HPLC) |
Damnum in Siccatio | ≤0.50% |
una immunditia | ≤0.50% |
Totalis immunditias | ≤1.0% |
Metalla gravis | ≤20ppm |
Test Standard | Enterprise Standard |
Consuetudinem | Ezetimibe (CAS: 163222-33-1) |
sarcina: Utrem, aluminium foil, pera, cardboard tympanum, 25kg/Drum, vel secundum exigentiam emptoris.
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine, umore et peste infestatione.
![1](https://www.ruifuchemical.com/uploads/15.jpg)
![2](https://www.ruifuchemical.com/uploads/23.jpg)
Shanghai Ruifu Chemical Co., Ltd. est primarius fabrica et supplementum 4-[[(4-Fluorophenyl)imino]methyl]-phenol (CAS: 3382-63-6) cum qualitate magna, media est Ezetimibae ( CAS: 163222-33-1).Ezetimibe est medicamentum ananti-hyperlipidemicum adhibitum ad gradus cholesteroli levandos.Ezetimibe est cholesterol vecturae inhibitoris quae ligat NPC1L1.Indicatur therapia adiunctiva in victu ad reductionem summi gradus totalis-C, LDL-C, et ApoB in patientibus primariis (heterozygois familiaribus et non familiaribus) hypercholesterolemia.